Flamma has agreed to acquire Lundbeck Pharmaceuticals Italy from H. Lundbeck, adding a pharmaceutical manufacturing facility in Padova to its operations. The transaction is expected to close Jan. 1, 2027, subject to customary closing conditions.
The acquisition will bring Flamma’s network in northern Italy to four active pharmaceutical ingredient manufacturing sites operating under current good manufacturing practice requirements. The company also has manufacturing operations in China and the United States.
The Padova facility will add up to 220 cubic meters of manufacturing capacity, increasing Flamma’s total capacity in Italy to approximately 1,100 cubic meters.
The site includes an API manufacturing workshop recently approved by Italy’s medicines regulator, AIFA. Its capabilities include hydrogenation, micronization, high-pressure chemistry, hazardous chemistry and high-containment manufacturing.
Flamma, based in Bergamo, provides contract development and manufacturing services for small molecule APIs, peptides and advanced intermediates. It said the acquisition will expand its capacity and technical capabilities for supporting pharmaceutical customers from early development through commercial supply.
Chairman and Chief Executive Gian Paolo Negrisoli said the purchase would add scientific, technical and operational capabilities across small molecule and peptide development programmes.
Lundbeck said its expected future requirements for small molecule manufacturing could be met by its facility in Lumsås, Denmark. Tine Bryan Stensbøl, interim head of product development and supply, cited that capacity in explaining the decision to sell the Italian operation.
Lazard is Flamma’s exclusive financial adviser, with NCTM Advant providing legal advice. Canaccord Genuity is Lundbeck’s exclusive financial adviser, while Baker McKenzie is its legal adviser for the transaction.